📊 CMMB Key Takeaways
Investment Thesis
Chemomab is a pre-revenue pharmaceutical company with significant cash burn and negative profitability, but maintains a strong balance sheet with $20.8M cash providing runway. The company is at a critical inflection point where clinical development progress and regulatory milestones will determine viability, presenting high execution risk typical of early-stage biotech.
CMMB Strengths
- Strong cash position of $20.8M with minimal debt provides runway for clinical development
- Excellent liquidity with 4.83x current ratio indicating ability to meet short-term obligations
- Zero debt/equity ratio eliminates refinancing and solvency risks
CMMB Risks
- Pre-revenue status with no commercial product generating income, entirely dependent on funding and cash reserves
- Severe cash burn of -$7.2M in operating cash flow demonstrates unsustainable burn rate relative to cash reserves
- Negative ROE of -31.3% and ROA of -25.0% indicate shareholder value destruction and asset inefficiency
- No revenue generation capability visible in current financial metrics creates existential business model risk
- Minimal insider trading activity (0 Form 4 filings in 90 days) suggests limited management confidence or activity
Key Metrics to Watch
- Quarterly operating cash burn rate and runway estimate based on current cash reserves
- Clinical trial progression, regulatory milestones, and FDA/EMA pathway updates
- Future financing activities and dilution impact from capital raises
CMMB Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 4.83x current ratio provides a solid financial cushion.
CMMB Profitability Ratios
CMMB vs Healthcare Sector
How Chemomab Therapeutics Ltd. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
CMMB Balance Sheet & Liquidity
CMMB 5-Year Financial Trend
5-Year Trend Summary: Chemomab Therapeutics Ltd.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $0.06 reflects profitable operations.
CMMB Growth Metrics (YoY)
CMMB Capital Allocation
CMMB SEC Filings
Access official SEC EDGAR filings for Chemomab Therapeutics Ltd. (CIK: 0001534248)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CMMB
What is the AI rating for CMMB?
Chemomab Therapeutics Ltd. (CMMB) has an AI rating of SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are CMMB's key strengths?
Strong cash position of $20.8M with minimal debt provides runway for clinical development. Excellent liquidity with 4.83x current ratio indicating ability to meet short-term obligations.
What are the risks of investing in CMMB?
Pre-revenue status with no commercial product generating income, entirely dependent on funding and cash reserves. Severe cash burn of -$7.2M in operating cash flow demonstrates unsustainable burn rate relative to cash reserves.
What is CMMB's revenue and growth?
Chemomab Therapeutics Ltd. reported revenue of N/A.
Does CMMB pay dividends?
Chemomab Therapeutics Ltd. does not currently pay dividends.
Where can I find CMMB SEC filings?
Official SEC filings for Chemomab Therapeutics Ltd. (CIK: 0001534248) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CMMB's EPS?
Chemomab Therapeutics Ltd. has a diluted EPS of $0.04.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.